Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Antidepressants that enhance both serotonergic and noradrenergic neurotransmission may be more effective than selective serotonin reuptake inhibitors (SSRIs) for acute-phase therapy of major depressive disorder. Mirtazapine in particular has been suggested to have a faster onset of action than reuptake inhibitors. The aim of this study is to compare the remission rates and time to remission in patients with major depression taking either mirtazapine or an SSRI in an all-inclusive set of studies. Data were obtained from all eligible randomized controlled studies contrasting mirtazapine and SSRIs. Meta-analyses of remission rates and time to remission, together with a supportive analysis of mean change from baseline Hamilton Depression Rating Scales-17 were performed, using individual patient data from 15 randomized controlled trials of mirtazapine (N = 1484) versus various SSRIs (N = 1487) across 6 weeks of double-blind therapy. Analyses were repeated for the eight studies that lasted at least 8 weeks. Remission rates for patients treated with mirtazapine were significantly higher when compared with those treated with an SSRI after 1 (3.4 vs. 1.6%, P = 0.0017), 2 (13.0 vs. 7.8%, P<0.0001), 4 (33.1 vs. 25.1%, P<0.0001), and 6 weeks (43.4 vs. 37.5%, P = 0.0006) of treatment. Mirtazapine-treated patients had a 74% higher likelihood of achieving remission during the first 2 weeks of therapy compared with patients treated with SSRIs. In conclusion, the findings indicate that mirtazapine may be a more rapidly effective antidepressant than SSRIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Keller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 1×
“Remission, defined as a virtually complete relief of symptoms, has become recognized as the optimal outcome of acute-phase treatment for major depression, as it is associated with reduced relapse risk, higher psychosocial functioning, and better long-term outcomes (Keller, 2003; Thase, 2003).”
BackgroundHigh prevalence of mental disorders in primary care
Ansseau, M., Dierick, M., Buntinkx, F., Cnockaert, P., De Smedt, J., Van Den Haute, M., & Vander Mijnsbrugge, D. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00219-7 · Cited by 352
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 1×
“(Papakostas et al., 2007; Nemeroff et al., 2008).”
Self-citationDouble-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
Schatzberg, A. F., Kremer, C., Rodrigues, H. E., & Murphy, G. M. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200209000-00007 · Cited by 215 · cited 1×
“…1998; Hong et al., 2003; Versiani et al., 2005), one compared mirtazapine versus citalopram (Leinonen et al., 1999), three compared mirtazapine versus paroxetine (Benkert et al., 2000; Schatzberg et al., 2002; Wade et al., 2003), and one compared mirtazapine versus sertraline (Behnke et al., 2003).”
ResultLeinonen, E., Skarstein, J., Behnke, K., ??gren, H., & Th Helsdingen, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00002 · Cited by 146
Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features
Guelfi, J. D., Ansseau, M., Timmerman, L., & Kørsgaard, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00010 · Cited by 138
Cited by
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions
Alam, A., Voronovich, Z., & Carley, J. A. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01525 · Cited by 84
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
Review of the use of mirtazapine in the treatment of depression
Benjamin, S., & Doraiswamy, P. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585459 · Cited by 46
Metadata
- Authors
- Thase, M. E., Nierenberg, A. A., Vrijland, P., van Oers, H. J. J., Schutte, A.-J., & Simmons, J. H.
- Venue
- International Clinical Psychopharmacology
- Published
- 2010-07
- Volume
- 25
- Issue
- 4
- Pages
- 189-198
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2075245372
- Cited by
- 90
- References
- 8
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. https://app.cochat.ai/papers/10.1097/yic.0b013e328330adb2
- The paper
- Thase, M. E., Nierenberg, A. A., Vrijland, P., van Oers, H. J. J., Schutte, A.-J., & Simmons, J. H. (2010). Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e328330adb2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.